Physician profile
Michelle E Burnham
NPI 1275781254
$2,690.62
in general payments reported to CMS, 2019-2025
25 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.52 · 2022: $84.66 · 2023: $120 · 2024: $1,077 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,593.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.89 | 2024-2025 | |
| Janssen Biotech, INC. | $364.77 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $280.69 | 2023-2025 | Taltz, Ebglyss, Zepbound |
| Leo Pharma INC. | $262.01 | 2024-2025 | Adbry, Anzupgo |
| Ucb, INC. | $199.52 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $166.20 | 2024-2025 | |
| Incyte Corporation | $136.44 | 2024-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $131.42 | 2024-2025 | |
| Organogenesis INC. | $83.44 | 2024-2025 | Puraply Am, Affinity |
| E.R. Squibb & Sons, L.L.C. | $76.45 | 2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $67.26 | 2024-2025 | |
| Biowound Solutions, INC. | $53.93 | 2025 | Bio-Connekt |
| Botanix Sb INC | $51.95 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.71 | 2024-2025 | Spevigo |
| Biofrontera INC. | $46.07 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $41.35 | 2022-2023 | Prolastin-C Liquid |
| Novo Nordisk INC | $35.99 | 2022-2023 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $35.01 | 2022-2023 | Abilify Asimtufii, Rexulti |
| Regeneron Healthcare Solutions, INC. | $24.67 | 2025 | Dupixent |
| Organon LLC | $19.21 | 2022-2025 | Vtama |
| Exact Sciences Corporation | $18.54 | 2023 | Cologuard Collection Kit |
| Reprise Biomedical, INC. | $16.82 | 2025 | Miro3d |
| Dexcom, INC. | $15.91 | 2023 | Dexcom G6 Transmitter |
| Zimvie INC. | $13.85 | 2022 | |
| Pfizer INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Burnham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.